Chemical and histochemical studies of postoperative sympathetic activity in the digestive tract in rats.

A. Dubois,I. Kopin,K. Pettigrew,D. Jacobowitz

DOI: https://doi.org/10.1016/S0016-5085(74)80140-X

IF: 29.4

1974-03-01

Gastroenterology

Abstract:

What problem does this paper attempt to address?

The Safety and Efficacy of Endovascular Treatment in Acute Ischemic Stroke Patients Caused by Large-Vessel Occlusion with Different Etiologies of Stroke: Data from ANGEL-ACT Registry

Raynald,Sun Dapeng,Huo Xiaochuan,Jia Baixue,Tong Xu,Ma Gaoting,Wang Anxin,Mo Dapeng,Ma Ning,Gao Feng,Amin Sheyar,Ren Zeguang,Miao Zhongrong

DOI: https://doi.org/10.1007/s13311-022-01189-9

2021-01-01

Neurology and Therapy

Abstract:Endovascular treatment’s (EVT) safety and efficacy have been proven in treating acute ischemic stroke (AIS) due to large vessel occlusion (LVO). However, limited data exist in different stroke subtypes. We aimed to investigate the differences in efficacy and safety of EVT for acute LVO according to different stroke subtypes. A total of 1635 AIS patients with LVO undergoing EVT from a prospective cohort of the Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke (ANGEL-ACT) registry were classified into three types according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. We compared the primary outcome: 90-day modified Rankin Scale (mRS) score, the secondary outcomes: 90-day mRS (0–1, 0–2, and 0–3), successful recanalization (mTICI 2b/3), and complete recanalization (mTICI 3), and the safety outcomes: death within 90 days, parenchymal hemorrhage (PH), and symptomatic intracranial hemorrhage (SICH) among the three subtypes of stroke patients. Then, multivariable logistic regression models adjusting for potential baseline-confounding variables to determine the associations between stroke subtypes and safety and efficacy endpoints were performed. Finally, we performed subgroup analyses to explore discrepancies in the relationships. EVT of cardioembolic LVO (CE-LVO) had a higher rate of mTICI 3 (71.7% vs. 65.9% and 63.2%; P = 0.024) and a higher rate of PH (13.8% vs. 5.4% and 6.7%; P < 0.001) when compared to other stroke subtypes. Even multivariable analysis demonstrated that CE-LVO was associated with mTICI 3 [adjusted odds ratio (OR), 1.50 (95% CI 1.04–2.17)] and PH [adjusted OR, 1.97 (95% CI 1.09–3.55)]. However, the 90-day mRS distribution and 90-day mRS (0–1, 0–2, and 0–3) did not differ among the stroke subtypes, and nor did the SICH (P > 0.05). Functional outcomes were similar among different stroke subtypes. Despite a higher rate of complete recanalization, there is an increased risk of parenchymal hemorrhage in CE-LVO. Clinical trial registration number: NCT03370939.
Abstract TP219: Outcomes and Differences by Occluded Vessel in the Endovascular Treatment for Acute Ischemic Stroke Patients With Medium Vessel Occlusion

Hidetoshi Matsukawa,Kazutaka Uchida,Conor Cunningham,Mohammad-Mahdi Sowlat,Sameh S Elawady,Ilko Maier,Sami Al Kasab,Pascal Jabbour,Joon-Tae Kim,Stacey Q Wolfe,Ansaar Rai,Robert M Starke,Marios Psychogios,Amir Shaban,Adam Arthur,Hugo Cuellar,Jonathan A Grossberg,Ali Alawieh,Daniele G. Romano,Omar Tanweer,Justin Mascitelli,Isabel Fragata,Adam Polifka,Joshua Osbun,Roberto Crosa,Charles Matouk,Min S Park,Michael Levitt,Waleed Brinjikji,Mark Moss,Travis Dumont,Richard Williamson,Pedro Navia,Peter Kan,Reade De Leacy,Shakeel Chowdhry,Mohamad Ezzeldin,Alejandro M Spiotta,Shinichi Yoshimura

DOI: https://doi.org/10.1161/str.55.suppl_1.tp219

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: The outcomes of mechanical thrombectomy (MT) for patients with acute ischemic stroke (AIS) caused by medium vessel occlusions (MeVOs) in different vessels remains unknown. The aim of this study is to investigate MT outcomes in AIS patients with isolated MeVOs in different occluded vessel segments using the data from an ongoing international multicenter registry, the Stroke Thrombectomy and Aneurysm Registry (STAR). The aim of this study is to investigate MT outcomes in AIS patients with isolated MeVOs in different occluded vessel segments using the data from an ongoing international multicenter registry, the Stroke Thrombectomy and Aneurysm Registry (STAR). Methods: 110 AIS patients with MeVO who undertook MT between January 2010 and December 2022 were retrospectively investigated. MeVO was defined as isolated occlusion of the A2 or A3 (A23O) segment of the anterior cerebral artery, M3 segment of the middle cerebral artery (M3O), and P2 or P3 segment of the posterior cerebral artery (P23O). The primary outcome measure was a 90-day modified Rankin score (mRS) 0-2. The 90-day mRS 0-1, any intracranial hemorrhage, symptomatic intracranial hemorrhage, and 90-day mortality were used as secondary outcomes. Outcomes were compared between A23O, M3O, and P23O. Results: Median (interquartile range) age was 68.3 (58.4-76.0) years and 49 patients were female (46.7%). MeVO included 17 A23O (15.5%), 60 M3O (54.5%), and 33 P23O (30.0%).Compared to patients with A23O (17.7%), those with M3O (56.7%) and P23O (45.5%) had a higher proportion of 90-day mRS 0-2 (M3O, adjusted odds ratio 10.3, 95% confidence interval 1.71-62.2, p = 0.01; P23O adjusted odds ratio 8.86, 95% confidence interval 1.32-59.3, p =0.02). Other outcomes showed no significant differences. Conclusions: This study indicates A2O might be related to poorer outcomes compared to M3O and P23 in MT treatment for AIS patients due to isolated MeVO. Efforts should be aimed at improving outcomes following A23O to match those at other MeVO locations.

peripheral vascular disease,clinical neurology
Exploring the Relationship Between Ischemic Core Volume and Clinical Outcomes after Thrombectomy or Thrombolysis

Chushuang Chen,Mark W Parsons,Christopher R Levi,Neil J Spratt,Ferdinand Miteff,Longting Lin,Xin Cheng,Min Lou,Tim Kleinig,Kenneth Butcher,Qiang Dong,Andrew Bivard

DOI: https://doi.org/10.1212/wnl.0000000000007768

IF: 9.9

2019-01-01

Neurology

Abstract:OBJECTIVE:To assess whether complete reperfusion after IV thrombolysis (IVT-R) would result in similar clinical outcomes compared to complete reperfusion after endovascular thrombectomy (EVT-R) in patients with a large vessel occlusion (LVO). METHODS:EVT-R patients were matched by age, clinical severity, occlusion location, and baseline perfusion lesion volume to IVT-R patients from the International Stroke Perfusion Imaging Registry (INSPIRE). Only patients with complete reperfusion on follow-up imaging were included. The excellent clinical outcome rates at day 90 on the modified Rankin Scale (mRS) were compared between EVT-R vs IVT-R patients within quintiles of increasing baseline ischemic core and penumbral volumes. RESULTS:From INSPIRE, there were 141 EVT-R patients and 141 matched controls (IVT-R) who met the eligibility criteria. In patients with a baseline core <30 mL, EVT-R resulted in a lower odds of achieving an excellent outcome at day 90 compared to IVT-R (day 90 mRS 0-1 odds ratio 0.01, p < 0.001). The group with a baseline core <30 mL contained mostly patients with distal M1 or M2 occlusions, and good collaterals (p = 0.01). In patients with a baseline ischemic core volume >30 mL (internal carotid artery and mostly proximal M1 occlusions), EVT-R increased the odds of patients achieving an excellent clinical outcome (day 90 mRS 0-1 odds ratio 1.61, p < 0.001) and there was increased symptomatic intracranial hemorrhage in the IVT-R group with core >30 mL (20% vs 3% in EVT-R, p = 0.008). CONCLUSION:From this observational cohort, LVO patients with larger baseline ischemic cores and proximal LVO, with poorer collaterals, clearly benefited from EVT-R compared to IVT-R alone. However, for distal LVO patients, with smaller ischemic cores and better collaterals, EVT-R was associated with a lower odds of favorable outcome compared to IVT-R alone.
Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial

Johanna M Ospel,Dar Dowlatshahi,Andrew Demchuk,David Volders,Markus Möhlenbruch,Shahid Nimjee,James Kennedy,Brian Buck,Jai Jai Shankar,Thomas C Booth,Mouhammad A Jumaa,Robert Fahed,Aravind Ganesh,Qiao Zhang,Craig Doram,Karla J Ryckborst,Michael D Hill,Mayank Goyal,the ESCAPE-MeVO investigators

DOI: https://doi.org/10.1177/17474930241262642

2024-06-23

International Journal of Stroke

Abstract:International Journal of Stroke, Ahead of Print. Rationale:Clinical outcomes in acute ischemic stroke due to medium vessel occlusion (MeVO) are often poor when treated with best medical management. Data from non-randomized studies suggest that endovascular treatment (EVT) may improve outcomes in MeVO stroke, but randomized data on potential benefits and risks are hitherto lacking. Thus, there is insufficient evidence to guide EVT decision-making in MeVO stroke.Aims:The primary aim of the ESCAPE-MeVO trial is to demonstrate that acute, rapid EVT in patients with acute ischemic stroke due to MeVO results in better clinical outcomes compared to best medical management. Secondary outcomes are to demonstrate the safety of EVT, its impact on self-reported health-related quality of life, and cost-effectiveness.Sample size estimates:Based on previously published data, we estimate a sample size of 500 subjects to achieve a power of 85% with a two-sided alpha of 0.05. To account for potential loss to follow-up, 530 subjects will be recruited.Methods and design:ESCAPE-MeVO is a multicenter, prospective, randomized, open-label study with blinded endpoint evaluation (PROBE design), clinicaltrials.gov: NCT05151172. Subjects with acute ischemic stroke due to MeVO meeting the trial eligibility criteria will be allocated in a 1:1 ratio to best medical care plus EVT versus best medical care only. Patients will be screened only at comprehensive stroke centers to determine if they are eligible for the trial, regardless of whether they were previously treated at a primary care center. Key eligibility criteria are (1) acute ischemic stroke due to MeVO that is clinically and technically eligible for EVT, (2) last-known well within the last 12 h, (3) National Institutes of Health Stroke Scale > 5 or 3–5 with disabling deficit, (4) high likelihood of salvageable tissue on non-invasive neuroimaging.Study outcomes:The primary outcome is the modified Rankin scale 90 days after randomization (shift analysis), whereby modified Rankin Score 5 and 6 will be collapsed into one category. Secondary outcomes include dichotomizations of the modified Rankin Score at 90 days, 24 h National Institutes of Health Stroke Score, difference between 24 h and baseline National Institutes of Health Stroke Score, mortality at 90 days, health-related quality of life (EQ-5D-5 L), Lawton scale of instrumental activities of daily living score, reperfusion quality (MeVO expanded Thrombolysis in Cerebral Infarction Score) and infarct volume at 24 h, and cost-effectiveness of endovascular recanalization. Safety outcomes include symptomatic and asymptomatic intracranial hemorrhage and procedural complications.Discussion:The ESCAPE-MeVO trial will demonstrate the effect of endovascular thrombectomy in addition to best medical management vis-à-vis best medical management in patients with acute ischemic stroke due to MeVO and provide data for evidence-based treatment decision-making in acute MeVO stroke.Data access statement:The raw data discussed in this mansucript will be made available by the corresponding author upon reasonable request.

peripheral vascular disease,clinical neurology
Benefit of endovascular treatment for primary versus secondary medium vessel occlusion: A multi‐center experience

Hai‐Zhou Hu,Yong‐Gang Zhao,Xin Liu,Xian‐Hui Sun,Thanh N. Nguyen,Hui‐Sheng Chen

DOI: https://doi.org/10.1111/cns.14687

2024-03-19

CNS Neuroscience & Therapeutics

Abstract:This study aimed to compare the clinical outcomes and safety of endovascular treatment (EVT) in patients with primary versus secondary medium vessel occlusion (MeVO). In MeVO patients who received EVT, there was higher likelihood of poor outcome in patients with secondary versus primary MeVO. Aims This study aimed to compare the clinical outcomes and safety of endovascular treatment (EVT) in patients with primary versus secondary medium vessel occlusion (MeVO). Methods From the endovascular treatment for acute ischemic stroke in the China registry, we collected consecutive patients with MeVO who received EVT. The primary endpoint was a good outcome, defined as a modified Rankin Scale (mRS) 0 to 2 at 90 days. Results 154 patients were enrolled in the final analysis, including 74 primary MeVO and 80 secondary MeVO. A good outcome at 90 days was achieved in 42 (56.8%) patients with primary MeVO and 33 (41.3%) patients with secondary MeVO. There was a higher probability of good outcomes in patients with the primary vs secondary MeVO (adjusted odds ratio, 2.16; 95% confidence interval, 1.04 to 4.46; p = 0.04). There were no significant differences in secondary and safety outcomes between MeVO groups. In the multivariable analysis, baseline ASPECTS (p = 0.001), final modified thrombolysis in cerebral infarction score (p = 0.01), and any ICH (p = 0.03) were significantly associated with good outcomes in primary MeVO patients, while baseline National Institutes of Health Stroke Scale (p = 0.002), groin puncture to recanalization time (p = 0.02), and early neurological improvement (p

pharmacology & pharmacy,neurosciences
Endovascular Thrombectomy Versus Medical Management in Isolated M2 Occlusions: Pooled Patient‐Level Analysis from the EXTEND‐IA Trials, INSPIRE, and SELECT Studies

Amrou Sarraj,Mark Parsons,Andrew Bivard,Ameer E. Hassan,Michael G. Abraham,Teddy Wu,Timothy Kleinig,Longting Lin,Chushuang Chen,Christopher Levi,Qiang Dong,Xin Cheng,Ken S. Butcher,Philip Choi,Nawaf Yassi,Darshan Shah,Gagan Sharma,Deep Pujara,Faris Shaker,Spiros Blackburn,Helen Dewey,Vincent Thijs,Clark W. Sitton,Geoffrey A. Donnan,Peter J. Mitchell,Bernard Yan,James G. Grotta,Gregory W. Albers,Stephen M. Davis,Bruce Campbell

DOI: https://doi.org/10.1002/ana.26331

IF: 11.2

2022-01-01

Annals of Neurology

Abstract:Objective The objective of this study was to evaluate functional and safety outcomes of endovascular thrombectomy (EVT) versus medical management (MM) in patients with M2 occlusion and examine their association with perfusion imaging mismatch and stroke severity. Methods In a pooled, patient-level analysis of 3 randomized controlled trials (EXTEND-IA, EXTEND-and IA-TNK parts 1 and 2) and 2 prospective nonrandomized studies (INSPIRE and SELECT), we evaluated EVT association with 90-day functional independence (modified Rankin Scale [mRS] = 0-2) in isolated M2 occlusions as compared to medical management overall and in subgroups by mismatch profile status and stroke severity. Results We included 517 patients (EVT = 195 and MM = 322), baseline median (interquartile range [IQR]) National Institutes of Health Stroke Scale (NIHSS) was 13 (8-19) in EVT versus 10 (6-15) in MM, p < 0.001. Pretreatment ischemic core did not differ (EVT = 10 [0-24] ml vs MM = 9 [3-21] ml, p = 0.59). Compared to MM, EVT was more frequently associated with functional independence (68.3 vs 61.6%, adjusted odds ratio [aOR] = 2.42, 95% confidence interval [CI] = 1.25-4.67, p = 0.008, inverse probability of treatment weights [IPTW]-OR = 1.75, 95% CI = 1.00-3.75, p = 0.05) with a shift toward better mRS outcomes (adjusted cOR = 2.02, 95% CI:1.23-3.29, p = 0.005), and lower mortality (5 vs 10%, aOR = 0.32, 95% CI = 0.12-0.87, p = 0.025). EVT was associated with higher functional independence in patients with a perfusion mismatch profile (EVT = 70.7% vs MM = 61.3%, aOR = 2.29, 95% CI = 1.09-4.79, p = 0.029, IPTW-OR = 2.02, 1.08-3.78, p = 0.029), whereas no difference was found in those without mismatch (EVT = 43.8% vs MM = 62.7%, p = 0.17, IPTW-OR: 0.71, 95% CI = 0.18-2.78, p = 0.62). Functional independence was more frequent with EVT in patients with moderate or severe strokes, as defined by baseline NIHSS above any thresholds from 6 to 10, whereas there was no difference between groups with milder strokes below these thresholds. Interpretation In patients with M2 occlusion, EVT was associated with improved clinical outcomes when compared to MM. This association was primarily observed in patients with a mismatch profile and those with higher stroke severity. ANN NEUROL 2022
Endovascular Treatment of Medium Vessel Occlusion Stroke

Johanna M. Ospel,Thanh N. Nguyen,Ashutosh P. Jadhav,Marios-Nikos Psychogios,Frédéric Clarençon,Bernard Yan,Mayank Goyal

DOI: https://doi.org/10.1161/strokeaha.123.036942

IF: 10.17

2024-01-19

Stroke

Abstract:Stroke, Ahead of Print. Approximately one-third of acute ischemic strokes with an identifiable vessel occlusion are caused by medium vessel occlusion (MeVO), that is, nonlarge vessel occlusions that are potentially amenable to endovascular treatment (EVT). Management of patients with MeVO is challenging in many ways: detecting MeVOs can be challenging, particularly for inexperienced physicians, and in busy clinical routine, MeVOs, therefore, remain sometimes undiagnosed. While the clinical course of MeVO stroke with medical management, including intravenous thrombolysis, is by no means, benign, it is more favorable compared with large vessel occlusion. At the same time, EVT complication rates are higher, and thus, the marginal benefit of EVT beyond best medical management is expected to be smaller and more challenging to detect if it were present. Several randomized controlled trials are currently underway to investigate whether and to what degree patients with MeVO may benefit from EVT and will soon provide robust data for evidence-based MeVO EVT decision-making. In this review, we discuss different ways of defining MeVOs, strategies to optimize MeVO detection on imaging, and considerations for EVT decision-making in the setting of MeVO stroke. We discuss the technical challenges related to MeVO EVT and conclude with an overview of currently ongoing MeVO EVT trials.

peripheral vascular disease,clinical neurology
Pretreatment predictors of very poor clinical outcomes in medium vessel occlusion stroke patients treated with mechanical thrombectomy

Vivek Yedavalli,Hamza Salim,Basel Musmar,Nimer Adeeb,Kareem El Naamani,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Benjamin YQ Tan,Jeremy J Heit,Robert W Regenhardt,Nicole M Cancelliere,Joshua D Bernstock,Aymeric Rouchaud,Jens Fiehler,Sunil Sheth,Muhammed Amir Essibayi,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Xavier Barreau,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Răzvan Alexandru Radu,Thomas R Marotta,Julian Spears,Takahiro Ota,Ashkan Mowla,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,James E Siegler,Thanh N Nguyen,Ricardo Varela,Amanda Baker,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Mohammad Ali Aziz-Sultan,Constantin Hecker,Hamza Shaikh,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Illario Tancredi,Tobias D Faizy,Erwah Kalsoum,Boris Lubicz,Aman B Patel,Vitor Mendes Pereira,Adrien Guenego,Adam A Dmytriw

DOI: https://doi.org/10.1177/17474930241270524

2024-08-21

International Journal of Stroke

Abstract:International Journal of Stroke, Ahead of Print. Background:Acute ischemic stroke (AIS) from primary medium vessel occlusions (MeVO) is a prevalent condition associated with substantial morbidity and mortality. Despite the common use of mechanical thrombectomy (MT) in AIS, predictors of poor outcomes in MeVO remain poorly characterized.Methods:In this prospectively collected, retrospectively reviewed, multicenter, multinational study, data from the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry were analyzed. The study included 1568 patients from 37 academic centers across North America, Asia, and Europe, treated with MT, with or without intravenous tissue plasminogen activator (IVtPA), between September 2017 and July 2021.Results:Among the 1568 patients, 347 (22.2%) experienced very poor outcomes (modified Rankin score (mRS), 5–6). Key predictors of poor outcomes were advanced age (odds ratio (OR): 1.03; 95% confidence interval (CI): 1.02 to 1.04; p < 0.001), higher baseline National Institutes of Health Stroke Scale (NIHSS) scores (OR: 1.07; 95% CI: 1.05 to 1.10; p < 0.001), pre-operative glucose levels (OR: 1.01; 95% CI: 1.00 to 1.02; p < 0.001), and a baseline mRS of 4 (OR: 2.69; 95% CI: 1.25 to 5.82; p = 0.011). The multivariable model demonstrated good predictive accuracy with an area under the receiver-operating characteristic (ROC) curve of 0.76.Conclusions:This study demonstrates that advanced age, higher NIHSS scores, elevated pre-stroke mRS, and pre-operative glucose levels significantly predict very poor outcomes in AIS-MeVO patients who received MT. These findings highlight the importance of a comprehensive risk assessment in primary MeVO patients for personalized treatment strategies. However, they also suggest a need for cautious patient selection for endovascular thrombectomy. Further prospective studies are needed to confirm these findings and explore targeted therapeutic interventions.

peripheral vascular disease,clinical neurology
Clinical and radiographic outcomes after mechanical thrombectomy in medium-vessel posterior cerebral artery occlusions: Subgroup analysis from STAR

Eyad Almallouhi,Matthew C Findlay,Ilko Maier,Pascal Jabbour,Joon-Tae Kim,Stacey Quintero Wolfe,Ansaar Rai,Robert M Starke,Marios-Nikos Psychogios,Amir Shaban,Nitin Goyal,Shinichi Yoshimura,Hugo Cuellar,Brian Howard,Ali Alawieh,Ali Alaraj,Mohamad Ezzeldin,Daniele G Romano,Omar Tanweer,Justin Mascitelli,Isabel Fragata,Adam Polifka,Fazeel Siddiqui,Joshua Osbun,Roberto Crosa,Charles Matouk,Min S Park,Michael R Levitt,Waleed Brinjikji,Mark Moss,Ergun Daglioglu,Richard Williamson Jr,Pedro Navia,Peter Kan,Reade De Leacy,Shakeel Chowdhry,David J Altschul,Alejandro Spiotta,Ramesh Grandhi

DOI: https://doi.org/10.1177/15910199241273839

2024-08-14

Abstract:Background: Whereas mechanical thrombectomy (MT) has become standard-of-care treatment for patients with salvageable brain tissue after acute stroke caused by large-vessel occlusions, the results of MT in patients with medium-vessel occlusions (MEVOs), particularly in the posterior cerebral artery (PCA), are not well known. Methods: Using data from the international Stroke Thrombectomy and Aneurysm Registry (STAR), we assessed presenting characteristics and clinical outcomes for patients who underwent MT for primary occlusions in the P2 PCA segment. As a subanalysis, we compared the PCA MeVO outcomes with STAR's anterior circulation MeVO outcomes, namely middle cerebral artery (MCA) M2 and M3 segments. Results: Of the 9812 patients in STAR, 43 underwent MT for isolated PCA MeVOs. The patients' median age was 69 years (interquartile range 61-79), and 48.8% were female. The median NIH Stroke Scale score was 9 (range 6-17). After recanalization, 67.4% of patients achieved successful recanalization (modified treatment in cerebral infarction score [mTICI] ≥ 2b), with a first-pass success rate of 44.2%, and 39.6% achieved a modified Rankin score of 0-2 at 90 days. Nine patients (20.9%) had died by the 90-day follow-up. In comparison with M2 and M3 MeVOs, there were no differences in presenting characteristics among the three groups. Patients with PCA MeVOs were less likely to undergo intra-arterial thrombolysis (4.7% PCA vs. 10.1% M2 vs. 16.2% M3, p = 0.046) or to achieve successful recanalization (mTICI ≥ 2b, 67.4%, 86.7%, 82.3%, respectively, p < 0.001); however, there were no differences in the rates of successful first-pass recanalization (44.2%, 49.8%, 52.3%, respectively, p = 0.65). Conclusions: We describe the STAR experience performing MT in patients with PCA MeVOs. Our analysis supports that successful first-pass recanalization can be achieved in PCA MEVOs at a rate similar to that in MCA MeVOs, although further study and possible innovation may be necessary to improve successful PCA MeVO recanalization rates.
Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

Huan Zhou,Wansi Zhong,Tingxia Zhang,Chenghua Xu,Genlong Zhong,Guomin Xie,Bing Zhang,Hongfang Chen,En Wang,Dongjuan Xu,Chaochan Cheng,Jiansheng Yang,Min Lou,Shenqiang Yan,on behalf of the CASE-II Study Group

DOI: https://doi.org/10.1161/strokeaha.123.044986

IF: 10.17

2024-05-26

Stroke

Abstract:Stroke, Volume 55, Issue 6, Page 1592-1600, June 1, 2024. BACKGROUND:Current evidence provides limited support for the superiority of endovascular thrombectomy (EVT) in patients with M2 segment middle cerebral artery occlusion. We aim to investigate whether imaging features of M2 segment occlusion impact the effectiveness of EVT.METHODS:We conducted a retrospective cohort study from January 2017 to January 2022, drawing data from the CASE II registry (Computer-Based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation), which specifically documented patients with acute ischemic stroke presenting with M2 segment occlusion undergoing reperfusion therapy. Patients were stratified into the intravenous thrombolysis (IVT) group (IVT alone) and EVT group (IVT plus EVT or EVT alone). The primary outcome was a modified Rankin Scale score 0 to 2 at 90 days. Secondary outcomes included additional thresholds and distribution of modified Rankin Scale scores, 24-hour recanalization, early neurological deterioration, and relevant complications during hospitalization. Safety outcomes encompassed intracranial hemorrhagic events at 24 hours and mortality at 90 days. Binary logistic regression analyses with propensity score matching were used. Subgroup analyses were performed based on the anatomic site of occlusion, including right versus left, proximal versus distal, dominant/co-dominant versus nondominant, single versus double/triple branch(es), and anterior versus central/posterior branch.RESULTS:Among 734 patients (43.3% were females; median age, 73 years) with M2 segment occlusion, 342 (46.6%) were in the EVT group. Propensity score matching analysis revealed no statistical difference in the primary outcome (odds ratio, 0.860 [95% CI, 0.611–1.209];P=0.385) between the EVT group and IVT group. However, EVT was associated with a higher incidence of subarachnoid hemorrhage (odds ratio, 6.655 [95% CI, 1.487–29.788];P=0.004) and pneumonia (odds ratio, 2.015 [95% CI, 1.364–2.977];P<0.001). Subgroup analyses indicated that patients in the IVT group achieved better outcomes when presenting with right, distal, or nondominant branch occlusion (Pall interaction<0.05).CONCLUSIONS:Our study showed similar efficiency of EVT versus IVT alone in acute M2 segment middle cerebral artery occlusion. This suggested that only specific patient subpopulations might have a potentially higher benefit of EVT over IVT alone.REGISTRATION:URL:https://clinicaltrials.gov; Unique identifier: NCT04487340.

peripheral vascular disease,clinical neurology
A review of endovascular treatment for medium vessel occlusion stroke

Johanna Maria Ospel,Mayank Goyal

DOI: https://doi.org/10.1136/neurintsurg-2021-017321

IF: 4.8

2021-02-26

Journal of NeuroInterventional Surgery

Abstract:Medium-vessel occlusions (MeVOs), that is, occlusions of the M2/3 middle cerebral artery, A2/3 anterior cerebral artery, and P2/3 posterior cerebral artery segments, account for 25%–40% of all acute ischemic stroke cases. Clinical outcomes of MeVO stroke with intravenous thrombolysis, which is the current standard of care, are moderate at best. With improving imaging technologies and a growing literature, MeVOs are increasingly recognized as a target for endovascular treatment (EVT). For the time being, there is limited but promising evidence for the safety and efficacy of MeVO EVT, and many neurointerventionists are already routinely offering EVT for MeVO stroke, despite the lack of clear guideline recommendations. In this article, we review the evidence on endovascular treatment for MeVO stroke and summarize the available literature on current imaging strategies, commonly used EVT selection criteria, EVT techniques, and outcome assessment for MeVO stroke.

surgery,neuroimaging
Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized Trial

Fouzi Bala,Nishita Singh,Katrina Ignacio,Ibrahim Alhabli,Ayoola Ademola,Anas Alrohimi,Houman Khosravani,Aleksander Tkach,Luciana Catanese,Dariush Dowlatshahi,Thalia Field,Gary Hunter,Faysal Benali,MacKenzie Horn,Andrew Demchuk,Michael Hill,Tolulope Sajobi,Brian Buck,Richard Swartz,Mohammed Almekhlafi,Bijoy K Menon

DOI: https://doi.org/10.5853/jos.2023.03713

Abstract:Background and purpose: The safety and efficacy of tenecteplase in patients with ischemic stroke due to medium vessel occlusion (MeVO) are not well studied. We aimed to compare tenecteplase with alteplase in stroke due to MeVO. Methods: Patients with baseline M2-middle cerebral artery (MCA), M3/M4-MCA, P2/P3/P4-posterior cerebral artery (PCA), A2/A3/A4-anterior cerebral artery (ACA) occlusions from the Alteplase Compared to Tenecteplase (AcT) trial were included. Primary outcome was the proportion of 90-day modified Rankin Scale (mRS) 0-1. Secondary outcomes were 90-day mRS 0-2, ordinal mRS, mortality, quality of life measures (EuroQol 5-Dimension 5-Level, EuroQol visual analog scale), and symptomatic intracerebral hemorrhage (sICH). Initial and final successful reperfusion were reported in patients undergoing endovascular thrombectomy (EVT). Results: Among 1,558 patients with available baseline computed tomography angiography; 455 (29.2%) had MeVO of which 27.5% (125/455) were proximal M2; 16.3% (74/455) were distal M2; 35.2% (160/455) were M3/M4; 7.5% (34/455) were A2/A3/A4; and 13.6% (62/455) were P2/P3/P4 occlusions. EVT was performed in 87/455 (19.1%) patients. mRS 0-1 at 90 days was achieved in 37.9% in the tenecteplase versus 34.7% in the alteplase group (adjusted risk ratio [aRR] 1.07; 95% confidence interval [CI] 0.91-1.25). Rates of 90-day mRS 0-2, sICH, and mortality were similar in both groups. No statistical difference was noted in initial successful reperfusion rates (13.0% vs. 7.5%) among the 87 patients who underwent endovascular thrombectomy. However, final successful reperfusion was higher in the tenecteplase group (71.7% vs. 60.0%, aRR 1.29, 95% CI 1.04-1.61). Conclusion: Intravenous tenecteplase had comparable safety, functional outcomes and quality of life compared to intravenous alteplase among patients with MeVO. Among those treated with EVT, tenecteplase was associated with higher successful reperfusion rates than alteplase.
Endovascular Versus Medical Management in Distal Medium Vessel Occlusion Stroke: The DUSK Study

Mahmoud H. Mohammaden,Lorena Souza Viana,Hend Abdelhamid,Marta Olive-Gadea,Marc Rodrigo-Gisbert,Manuel Requena,Pedro N. Martins,Stavros Matsoukas,Braxton R. Schuldt,Johanna T. Fifi,Mudassir Farooqui,Juan Vivanco-Suarez,Santiago Ortega-Gutierrez,Piers Klein,Mohamad Abdalkader,Nicholas Vigilante,James E. Siegler,Felipe Moreira Ferreira,Sophia Peng,Ali Alaraj,Diogo C. Haussen,Thanh N. Nguyen,Raul G. Nogueira

DOI: https://doi.org/10.1161/strokeaha.123.045228

IF: 10.17

2024-05-26

Stroke

Abstract:Stroke, Volume 55, Issue 6, Page 1489-1497, June 1, 2024. BACKGROUND:Endovascular treatment (EVT) is part of the usual care for proximal vessel occlusion strokes. However, the safety and effectiveness of EVT for distal medium vessel occlusions remain unclear. We sought to compare the clinical outcomes of EVT to medical management (MM) for isolated distal medium vessel occlusions.METHODS:This is a retrospective analysis of prospectively collected data from seven comprehensive stroke centers. Patients were included if they had isolated distal medium vessel occlusion strokes due to middle cerebral artery M3/M4, anterior cerebral artery A2/A3, or posterior cerebral artery P1/P2 segments. Patients treated with EVT or MM were compared with multivariable logistic regression and inverse probability of treatment weighting. The primary outcome was the shift in the degree of disability as measured by the modified Rankin Scale (mRS) at 90 days. Secondary outcomes included 90-day good (mRS score, 0–2) and excellent (mRS score, 0–1) outcomes. Safety measures included symptomatic intracranial hemorrhage and 90-day mortality.RESULTS:A total of 321 patients were included in the analysis (EVT, 179; MM, 142; 40.8% treated with intravenous thrombolysis). In the inverse probability of treatment weighting model, there were no significant differences between EVT and MM in terms of the overall degree of disability (mRS ordinal shift; adjusted odds ratio [aOR], 1.25 [95% CI, 0.95–1.64];P=0.110), rates of good (mRS score, 0–2; aOR, 1.32 [95% CI, 0.97–1.80];P=0.075) and excellent (aOR, 1.32 [95% CI, 0.94–1.85];P=0.098) outcomes, or mortality (aOR, 1.20 [95% CI, 0.78–1.85];P=0.395) at 90 days. The multivariable regression model showed similar findings. Moreover, there was no difference between EVT and MM in rates of symptomatic intracranial hemorrhage in the multivariable regression model (aOR, 0.57 [95% CI, 0.21–1.58];P=0.277), but the inverse probability of treatment weighting model showed a lower likelihood of symptomatic intracranial hemorrhage (aOR, 0.46 [95% CI, 0.24–0.85];P=0.013) in the EVT group.CONCLUSIONS:This multicenter study failed to demonstrate any significant outcome differences among patients with isolated distal medium vessel occlusions treated with EVT versus MM. These findings reinforce clinical equipoise. Randomized clinical trials are ongoing and will provide more definite evidence.

peripheral vascular disease,clinical neurology
Earlier endovascular thrombectomy and mortality in patients with anterior circulation large vessel occlusion: a propensity-matched analysis of the Stroke Thrombectomy and Aneurysm Registry (STAR)

Hidetoshi Matsukawa,Roberto Crosa,Conor Cunningham,Ilko Maier,Sami Al Kasab,Pascal Jabbour,Joon-Tae Kim,Stacey Quintero Wolfe,Ansaar Rai,Robert M. Starke,Marios-Nikos Psychogios,Amir Shaban,Nitin Goyal,Shinichi Yoshimura,Hugo Cuellar,Brian Howard,Ali Alawieh,Ali Alaraj,Mohamad Ezzeldin,Daniele G. Romano,Omar Tanweer,Justin Mascitelli,Isabel Fragata,Adam Polifka,Fazeel Siddiqui,Joshua Osbun,Charles Matouk,Min S. Park,Michael R. Levitt,Waleed Brinjikji,Mark Moss,Richard Williamson,Pedro Navia,Peter Kan,Reade De Leacy,Shakeel Chowdhry,Alejandro M. Spiotta

DOI: https://doi.org/10.1016/j.wneu.2024.06.082

IF: 2.21

2024-06-22

World Neurosurgery

Abstract:Background The definitive impact of onset to arterial puncture time (OPT) on 90-day mortality after endovascular thrombectomy (EVT) in patients with acute cerebral infarction (AIS) caused by anterior circulation large vessel occlusion (LVO) remains unknown. The present study aimed to evaluate the influence of OPT on 90-day mortality in anterior circulation AIS-LVO patients who underwent EVT. Methods Data from 33 international centers were retrospectively analyzed. The receiver operating characteristic curve analysis was used to identify a cutoff for OPT. A propensity score-matched analysis was performed. The primary outcome was 90-day mortality (modified Rankin Scale [mRS] 6). Secondary outcomes included mortality at discharge, 90-day good outcome (mRS 0-2), 90-day poor outcome (mRS 5-6), successful recanalization (defined as post-procedure modified Thrombolysis in Cerebral Infarction scale ≥2b), and intracranial hemorrhage. Results 2,842 AIS-LVO patients with EVT were included. The cutoff for OPT for 90-day mortality was 180 min. 378 patients had OPT < 180 min and 378 patients had OPT ≥ 180 min in the propensity score-matched cohort (n=756). Patients with OPT < 180 min were less likely to have 90-day mortality (odds ratio [OR] 0.70, 95% confidence interval [CI] 0.51–0.96) and poor outcome (OR 0.71, 95% CI 0.53–0.96), and more likely to have 90-day good outcome (OR 1.55, 95% CI 1.16–2.08). Other outcomes showed no significant differences. Conclusions This study showed that OPT < 180 min was less related to 90-day mortality and poor outcome, and more to 90-day good outcome in AIS-LVO patients who underwent EVT.

surgery,clinical neurology
Endovascular Treatment for Minor Acute Ischemic Strokes with Large Vessel Occlusion

Rui Xue,Wansi Zhong,Ying Zhou,Yaode He,Shenqiang Yan,Zhicai Chen,Jianan Wang,Xiaoxian Gong,Min Lou

DOI: https://doi.org/10.1161/jaha.122.027326

2022-01-01

Abstract:Background It remains uncertain whether patients with minor acute ischemic stroke with large vessel occlusion benefit from endovascular treatment (EVT). We aim to evaluate the outcomes of EVT in minor acute ischemic stroke with anterior circulation large vessel occlusion. Methods and Results Based on a nationwide prospective stroke registry, patients with minor acute ischemic stroke with anterior circulation large vessel occlusion within 24 hours of onset were divided into groups receiving standard medical treatment plus EVT or standard medical treatment alone. Primary outcome was excellent functional outcome defined as modified Rankin Scale score 0 to 1 at 90 days. In addition, a multivariable logistic regression model was used to analyze the effect of EVT guided by perfusion imaging. A total of 572 patients with median age 68 years (interquartile range=60–77) and median National Institutes of Health Stroke score 3 (interquartile range =2–4) were identified and 123 patients were treated with standard medical treatment plus EVT. EVT was not associated with excellent functional outcome (unadjusted odds ratio [OR], 0.771 [95% CI, 0.516–1.151]; adjusted OR, 0.793 [95% CI, 0.515–1.219]; P=0.290). However, therapy selection guided by perfusion imaging was a modifier of EVT effect on outcomes, as EVT was significantly associated with excellent functional outcome (60.0% versus 50.8%, unadjusted OR, 1.451 [95% CI, 0.643–3.272]; adjusted OR, 2.849 [95% CI, 1.006–8.067]; P=0.049) but not with symptomatic intracerebral hemorrhage in the imaging‐guided group. Conclusions Although functional outcomes in minor acute ischemic stroke caused by anterior circulation large vessel occlusion were not improved from the routine use of EVT, our results suggested that EVT guided by perfusion imaging could be beneficial for those patients. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT 04487340.
Abstract TP189: Outcome Differences Between Endovascular Thrombectomy and Medical Management Based on Underlying Stroke Etiology: A Secondary Analysis of SELECT2 Trial

Faris Shaker,Deep Pujara,Michael G Abraham,Michael Chen,Scott E Kasner,Santiago Ortega-Gutierrez,Muhammad S Hussain,Spiros Blackburn,Leonid Churilov,Sophia Sundararajan,Yin Hu,Wei Xiong,Michael DeGeorgia,Amanda Opaskar,Rami Moussa,Mohammad Abdulrazzak,Faisal Al-Shaibi,Kelsey R Duncan,Hannah Johns,Cathy A Sila,Anthony J Furlan,Vitor Mendes Pereira,Michael D Hill,James C Grotta,Marc Ribo,Ameer E Hassan,Bruce Campbell,Amrou Sarraj,

DOI: https://doi.org/10.1161/str.55.suppl_1.tp189

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: In patients with large core ischemic stroke, potential heterogeneity in EVT treatment effect based on underlying etiology is an important question. We explored differences in clinical outcomes and successful recanalization rates between EVT and MM. Methods: From SELECT2 randomized clinical trial, patients were categorized based on Stroke etiology: Large-artery atherosclerosis (LAA), Cardioembolism (CE), Stroke of other determined etiology (SOE), and Stroke of undetermined etiology (SUE). Procedure success, clinical outcomes and EVT treatment effect was compared based on stroke etiology. Results: Cardioembolic stroke was most frequently observed etiology across the trial (41%), followed by stroke of undetermined etiology (29%), large artery atherosclerosis (23%) and stroke of other determined etiology (6%). Proportion of patients achieving successful reperfusion (mTICI 2b-3) after EVT differed significantly across the categories (CE: 87%, LAA: 82%, SOE: 73%, SUE: 66%, p=0.040). However, treatment effect estimates favored EVT across categories of stroke etiology without significant heterogeneity - CE (ref): aGenOR: 1.83 (1.30-2.59) vs LAA: aGenOR: 2.04 (1.24-3.37), p-int: 0.87 vs SOE: aGenOR: 2.06 (0.80-5.28), p-int: 0.79 vs SUE: aGenOR: 1.20 (0.77-1.88), p-int: 0.17. Conclusion: In patients with large core ischemic stroke, proportion of patients achieving successful reperfusion differed based on stroke etiology. However, EVT was associated with better outcomes without evidence of significant heterogeneity. Further optimization of procedure techniques may help improve successful reperfusion rates and clinical outcomes in patients with SUE. Clinicaltrials.gov registration: NCT03876457

peripheral vascular disease,clinical neurology
Anesthesia modality in endovascular treatment for distal medium vessel occlusion stroke: intention-to-treat propensity score-matched analysis

Mahmoud H Mohammaden,Mohamed F Doheim,Hend Abdelhamid,Stavros Matsoukas,Braxton Riley Schuldt,Johanna T Fifi,Okkes Kuybu,Bradley A Gross,Alhamza R Al-Bayati,Jaydevsinh Dolia,Jonathan A Grossberg,Marta Olive-Gadea,Marc Rodrigo-Gisbert,Manuel Requena,Andre Monteiro,Siyuan Yu,James E Siegler,Aaron Rodriguez-Calienes,Milagros Galecio-Castillo,Santiago Ortega-Gutierrez,Gustavo M Cortez,Ricardo A Hanel,Amin Aghaebrahim,Ameer E Hassan,Thanh N Nguyen,Mohamad Abdalkader,Piers Klein,Mohamed M Salem,Jan-Karl Burkhardt,Brian T Jankowitz,Marco Colasurdo,Peter Kan,Muhammad Hafeez,Omar Tanweer,Sophia Peng,Ali Alaraj,Adnan H Siddiqui,Raul G Nogueira,Diogo C Haussen

DOI: https://doi.org/10.1136/jnis-2024-021668

2024-05-23

Abstract:Background: The optimal anesthesia modality during endovascular treatment (EVT) for distal medium vessel occlusion (DMVO) stroke is uncertain. We aimed to evaluate the association of the anesthesia modality with procedural and clinical outcomes following EVT for DMVO stroke. Methods: This is a multicenter retrospective analysis of a prospectively collected database. Patients were included if they had DMVO involving the middle cerebral artery-M3/4, anterior cerebral artery-A2/3, or posterior cerebral artery-P1/P2-3, and underwent EVT. The cohort was divided into two groups, general anesthesia (GA) and non-general anesthesia (non-GA), and compared based on the intention-to-treat principle as primary analysis. We used propensity scores to balance the two groups. The primary outcome was the shift in the degree of disability as measured by the 90-day modified Rankin Scale (mRS). Secondary outcomes included successful reperfusion, as well as excellent (mRS 0-1) and good (mRS 0-2) clinical outcomes at 90 days. Safety measures included procedural complications, symptomatic intracerebral hemorrhage (sICH), and 90-day mortality. Results: Among 366 DMVO thrombectomies, 61 matched pairs were eligible for analysis. Median age and National Institutes of Health Stroke Scale score as well as other baseline demographic and clinical characteristics were balanced between both groups. The GA group had no difference in the overall degree of disability (common OR 1.19, 95% CI 0.52 to 2.86, P=0.67) compared with the non-GA arm. Likewise, the GA group had comparable rates of successful reperfusion (OR 2.38, 95% CI 0.80 to 7.07, P=0.12), good/excellent clinical outcomes (OR 1.14, 95% CI 0.44 to 2.96, P=0.79/(OR 0.65, 95% CI 0.24 to 1.81, P=0.41), procedural complications (OR 1.00, 95% CI 0.19 to 5.16, P>0.99), sICH (OR 3.24, 95% CI 0.83 to 12.68, P=0.09), and 90-day mortality (OR 1.43, 95% CI 0.48 to 4.27, P=0.52) compared with the non-GA group. Conclusions: In patients with DMVO, our study showed that GA and non-GA groups had similar procedural and clinical outcomes, as well as safety measures. Further larger controlled studies are warranted.
214 Technical and Clinical Outcomes in Patients With Short-term Repeated Mechanical Thrombectomy: An International Multicenter Study

Hassan Saad,Youssef M. Zohdy,Brian M. Howard,C. Michael Cawley,Aqueel Hussain Pabaney,Laurie Dimisko,Ali M. Alawieh,Ilko Maier,Alejandro M. Spiotta,Pascal Jabbour,Stacey Q. Wolfe,Ansaar Rai,Joon-Tae Kim,Justin Robert Masitelli,Robert M. Starke,Amir Shaban,Shinichi Yoshimura,Reade De Leacy,Peter T. Kan,Isabel Fragata,Adam J. Polifka,Adam S. Arthur,Min S. Park,Charles Matouk,Michael Robert Levitt,Stavropoula I. Tjoumarkaris,Jan Liman,Kyle Michael Fargen,Jonathan Andrew Grossberg

DOI: https://doi.org/10.1227/neu.0000000000002809_214

IF: 5.315

2024-04-01

Neurosurgery

Abstract:INTRODUCTION: Endovascular thrombectomy (EVT) remains the standard of care for acute large vessel occlusion (LVO) stroke. However, the safety and efficacy of repeat EVT (rEVT) in recurrent LVO remains unclear. METHODS: Data were included from the Stroke Thrombectomy and Aneurysm Registry (STAR) with 21 stroke centers for EVT performed to treat LVO stroke from 2013-2022. Patients undergoing single or rEVT within 30 days were included. Propensity score matching was used to compare patients undergoing single versus rEVT. The primary outcome was the modified Rankin score(mRS) at 90 days, and secondary outcomes were successful recanalization, postprocedural hemorrhage and mortality. RESULTS: Out of a total of 7387 patients who underwent EVT for LVO stroke, 90(1.2%) patients underwent rEVT for the same vascular territory within 30 days. The average time to re-occlusion was 5.3±7.3 days, and 41(45.6%) patients required rEVT within 24hrs. Patients undergoing rEVT had comparable rate of good functional outcome and mortality rate, but with but higher rate of symptomatic intracranial hemorrhage compared to a matched cohort of patients undergoing single procedure. There was a significant reduction in NIHSS before rEVT and at discharge (ΔNIHSS=(-)5 ± 1; p = 0.006). The rate of successful recanalization was similar in single and rEVT groups (78% versus 80%, p = 0.78) and between index and rEVT performed on the same patients (79% versus 80%; p = 0.78). CONCLUSIONS: Short-term rEVT is associated with comparable functional outcomes but with higher rate of hemorrhagic conversion compared to patients undergoing single EVT.

surgery,clinical neurology
The effect of nanotopography on modulating protein adsorption and the fibrotic response.

K. Kam,Laura A. Walsh,S. Bock,J. Ollerenshaw,Russell F. Ross,T. Desai

DOI: https://doi.org/10.1089/ten.TEA.2012.0772

Abstract:Understanding and modulating the cellular response to implanted biomaterials is crucial for the field of tissue engineering and regenerative medicine. Since cells typically reside in an extracellular matrix containing nanoscale architecture, identifying synthetic nanostructures that induce desirable cellular behaviors could greatly impact the field. Using nanoimprint lithography, nanostructured patterns were generated on thin film polymeric materials. The ability of these surfaces to influence protein adsorption, fibroblast proliferation and morphology, and fibrotic markers was investigated. Nanostructured features with aspect ratios greater than five allowed for less protein adsorption, resulting in decreased fibroblast proliferation and rounded cellular morphology. These nanofeatures also induced significantly lower gene expression of collagen 1α2, collagen 3α1, and growth factors such as connective tissue growth factor, integrin linked kinase, transforming growth factor β1 (TGF-β1), and epidermal growth factor, key factors associated with a fibrotic response. The results demonstrate that select nanostructured surfaces could be used to modulate the fibrotic behavior in cells and have the potential to be used as antifibrotic architecture for medical implants or tissue engineering scaffolds.
Abstract WMP95: Anesthesia Modality in Endovascular Treatment for Distal Medium Vessel Occlusion Stroke: Intention-to-Treat Matched Analysis

Mahmoud H Mohammaden,Mohamed F Dohiem,Hend M Abdelhamid,stavros matsoukas,Braxton R Schuldt,Fifi Johanna,Okkes Kuybu,Bradley Gross,Alhamza R Al-Bayati,Jaydevsinh Dolia,Marta Olive-Gadea,Marc Rodrigo-Gisbert,Manuel Requena,Andre Monteiro,Si Yu,James E Siegler,Mudassir Farooqui,Juan Vivanco-Suarez,Santiago Ortega-Gutierrez,Gustavo Cortez,Ricardo Hanel,Ameer E Hassan,Thanh Nguyen,Mohamad AbdalKader,Piers Klein,Mohamed M Salem,Jan-Karl Burkhardt,Brian Jankowitz,Marco Colasurdo,Peter Kan,Muhammad Hafeez,Omar Tanweer,Sophia Peng,Ali A Alaraj,Adnan Siddiqui,Raul G Nogueira,Diogo C Haussen

DOI: https://doi.org/10.1161/str.55.suppl_1.wmp95

IF: 10.17

2024-02-01

Stroke

Abstract:Background: The optimal anesthesia modality during endovascular treatment (EVT) for distal medium vessel occlusion (DMVO) strokes is uncertain. We aimed to evaluate the impact of the anesthesia modality on procedural and clinical outcomes following EVT for DMVO strokes. Methods: This is a retrospective analysis of a prospectively collected database from 14 comprehensive stroke centers in the United States and Europe. Patients were included if they had DMVO due to MCA-M3/4, ACA-A1/A2-3, or PCA-P1/P2-3 and underwent EVT. The cohort was divided into two groups: general anesthesia (GA) and non-general anesthesia (non-GA). The primary analysis compared the two groups based on the intention-to-treat principle. The secondary analysis compared both groups according to the as-treated approach. We used propensity scores to balance the two groups at a 1:1 ratio. The primary outcome was the shift in the degree of disability as measured by the 90-day mRS. Secondary outcomes included successful reperfusion, mRS0-1, and mRS0-2 at 90-days. Safety measures included procedural complications, symptomatic intracerebral hemorrhage (sICH), and 90-day mortality. Results: A total of 365 patients were eligible for analysis. In the intention-to-treat analysis (130 matched pairs), baseline demographic and clinical characteristics were balanced. There was no difference in the degree of disability (mRS ordinal shift; acOR 1.64, 95%-CI [0.78-3.46], P=0.19) between the two groups. GA had comparable rates of successful reperfusion (aOR2.66, 95%CI [0.75-9.42],P=0.13), 90-day mRS0-1 (aOR1.07, 95%CI[0.41-2.78],P=0.89), 90-day mRS0-2 (aOR1.46, 95%CI[0.60-3.55],P=0.41), procedural complications (aOR1.08, 95%CI[0.20-5.79],P=0.93), sICH (aOR3.28, 95%CI[0.81-13.34], P=0.10), and 90-day mortality (aOR0.82, 95%CI [0.35-1.95],P=0.66) compared to the non-GA group. Similarly, when comparing 150 matched pairs using the as-treated principle, GA and non-GA showed comparable outcomes. Conclusions: In patients with DMVO undergoing EVT, GA and non-GA had similar procedural and clinical outcomes, as well as safety measures. Further, larger controlled studies are warranted.

peripheral vascular disease,clinical neurology

Chemical and histochemical studies of postoperative sympathetic activity in the digestive tract in rats.

The Safety and Efficacy of Endovascular Treatment in Acute Ischemic Stroke Patients Caused by Large-Vessel Occlusion with Different Etiologies of Stroke: Data from ANGEL-ACT Registry

Abstract TP219: Outcomes and Differences by Occluded Vessel in the Endovascular Treatment for Acute Ischemic Stroke Patients With Medium Vessel Occlusion

Exploring the Relationship Between Ischemic Core Volume and Clinical Outcomes after Thrombectomy or Thrombolysis

Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial

Benefit of endovascular treatment for primary versus secondary medium vessel occlusion: A multi‐center experience

Endovascular Thrombectomy Versus Medical Management in Isolated M2 Occlusions: Pooled Patient‐Level Analysis from the EXTEND‐IA Trials, INSPIRE, and SELECT Studies

Endovascular Treatment of Medium Vessel Occlusion Stroke

Pretreatment predictors of very poor clinical outcomes in medium vessel occlusion stroke patients treated with mechanical thrombectomy

Clinical and radiographic outcomes after mechanical thrombectomy in medium-vessel posterior cerebral artery occlusions: Subgroup analysis from STAR

Comparing Outcomes of Thrombectomy Versus Intravenous Thrombolysis Based on Middle Cerebral Artery M2 Occlusion Features

A review of endovascular treatment for medium vessel occlusion stroke

Tenecteplase Versus Alteplase in Medium Vessel Occlusion Ischemic Stroke: A Secondary Analysis of the Alteplase Compared to Tenecteplase Randomized Trial

Endovascular Versus Medical Management in Distal Medium Vessel Occlusion Stroke: The DUSK Study

Earlier endovascular thrombectomy and mortality in patients with anterior circulation large vessel occlusion: a propensity-matched analysis of the Stroke Thrombectomy and Aneurysm Registry (STAR)

Endovascular Treatment for Minor Acute Ischemic Strokes with Large Vessel Occlusion

Abstract TP189: Outcome Differences Between Endovascular Thrombectomy and Medical Management Based on Underlying Stroke Etiology: A Secondary Analysis of SELECT2 Trial

Anesthesia modality in endovascular treatment for distal medium vessel occlusion stroke: intention-to-treat propensity score-matched analysis

214 Technical and Clinical Outcomes in Patients With Short-term Repeated Mechanical Thrombectomy: An International Multicenter Study

The effect of nanotopography on modulating protein adsorption and the fibrotic response.

Abstract WMP95: Anesthesia Modality in Endovascular Treatment for Distal Medium Vessel Occlusion Stroke: Intention-to-Treat Matched Analysis